The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
CORONARY INTERVENTIONS
Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial
EuroIntervention 2016;12:e167-e174 published online e-edition June 2016. DOI: 10.4244/EIJV12I2A30
Jochen Wöhrle1*, MD; Sinisa Markovic1, MD; Wolfgang Rottbauer1, MD; Toshiya Muramatsu2, MD; Kazushige Kadota3, MD; Nicolás Vázquez-González4, MD; Jacob Odenstedt5, MD; Antonio Serra6, MD; David Antoniucci7, MD; Olivier Varenne8, MD; Shigeru Saito9, MD; William Wijns10, MD; on behalf of the CENTURY II Investigators
1. Department of Internal Medicine II, University of Ulm, Ulm, Germany; 2. Department of Cardiology, Saiseikai Yokohama City Eastern Hospital, Kanagawa, Japan; 3. Department of Cardiology, Kurashiki Central Hospital, Okayama, Japan; 4. Cardiac Catheteriza
Aims: CENTURY II is a prospective, multicentre, randomised, single-blind trial comparing the bioresorbable polymer sirolimus-eluting Ultimaster® stent (BP-SE